Pieris Pharmaceuticals (NASDAQ:PIRS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) in a research report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

PIRS opened at $1.21 on Thursday. Pieris Pharmaceuticals has a one year low of $0.85 and a one year high of $3.34. The company has a market cap of $90.04 million, a P/E ratio of -2.57 and a beta of 1.17. The business’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.24.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PIRS. Rafferty Asset Management LLC grew its stake in Pieris Pharmaceuticals by 32.3% during the 2nd quarter. Rafferty Asset Management LLC now owns 29,622 shares of the biotechnology company’s stock worth $55,000 after buying an additional 7,240 shares during the last quarter. Hsbc Holdings PLC grew its stake in Pieris Pharmaceuticals by 55.6% during the 1st quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company’s stock worth $63,000 after buying an additional 7,343 shares during the last quarter. Raymond James & Associates grew its stake in Pieris Pharmaceuticals by 50.0% during the 4th quarter. Raymond James & Associates now owns 30,000 shares of the biotechnology company’s stock worth $31,000 after buying an additional 10,000 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Pieris Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Blair William & Co. IL grew its stake in Pieris Pharmaceuticals by 9.1% during the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company’s stock worth $390,000 after buying an additional 10,760 shares during the last quarter. Hedge funds and other institutional investors own 47.31% of the company’s stock.

Pieris Pharmaceuticals Company Profile

(Get Rating)

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.